Simulations Plus (SLP)
Builds drug-development simulation software and consulting services for biopharma clients.
$18.41
After hours0.00 (0.00%)
At close$18.41(−0.11%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Aug 2023 | Q1 FY24Nov 2023 | Q2 FY24Feb 2024 | Q3 FY24May 2024 | Q4 FY24Aug 2024 | Q1 FY25Nov 2024 | Q2 FY25Feb 2025 | Q3 FY25May 2025 | Q4 FY25Aug 2025 | Q1 FY26Nov 2025 | Q2 FY26Feb 2026 | Q3 FY26May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 15 | 18 | 19 | 19 | 19 | 22 | 20 | 17 | 18 | 24 | 22 |
| Cost of revenue | 3 | 5 | 5 | 5 | 12 | 9 | 9 | 7 | 8 | 8 | 8 | 7 |
| Gross profit | 12 | 10 | 13 | 13 | 7 | 10 | 13 | 13 | 10 | 11 | 16 | 15 |
| 13 | 9 | 9 | 11 | 8 | 10 | 10 | 87 | 9 | 10 | 11 | 11 | |
| Research & development | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 3 |
| 11 | 8 | 7 | 10 | 6 | 8 | 8 | 9 | 8 | 7 | 7 | 7 | |
| Selling & marketing | 0 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 |
| General & administrative | 0 | 6 | 6 | 8 | 3 | 5 | 5 | 6 | 5 | 4 | 4 | 5 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 1 | 4 | 2 | −1 | 0 | 3 | −74 | 1 | 1 | 6 | 4 |
| 0 | 1 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −3 | −1 | −1 | −2 | −2 | 0 | −1 | −77 | 0 | 0 | 0 | 1 |
| Income before tax | 0 | 2 | 5 | 4 | 1 | 0 | 4 | −74 | 1 | 1 | 6 | 5 |
| Income tax expense | 0 | 0 | 1 | 1 | 0 | 0 | 0 | −7 | 2 | 0 | 1 | 1 |
| Net income from continuing operations | 1 | 2 | 4 | 3 | 1 | 0 | 3 | −67 | −1 | 1 | 5 | 4 |
| Net income | 1 | 2 | 4 | 3 | 1 | 0 | 3 | −67 | −1 | 1 | 5 | 4 |
| EPS, basic | $0.03 | $0.10 | $0.20 | $0.16 | $0.04 | $0.01 | $0.15 | −$3.35 | −$0.03 | $0.03 | $0.23 | $0.18 |
| EPS, diluted | $0.03 | $0.10 | $0.20 | $0.15 | $0.04 | $0.01 | $0.15 | −$3.35 | −$0.03 | $0.03 | $0.22 | $0.18 |
| Weighted average shares, basic | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Weighted average shares, diluted | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| EBITDA | 4 | 3 | 6 | 5 | 3 | 3 | 6 | 5 | 2 | 2 | 7 | 1 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | −3 |
| EBIT | 3 | 2 | 5 | 4 | 1 | 0 | 4 | 3 | 1 | 1 | 6 | 4 |